1. Scrip
  2. >>R&D

Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos

‘Standstill’ Guarantees Biotech’s Independence

 
• By Andrew McConaghie

$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.

Jefferies_Stolpe
Galapagos CEO Onno van de Stolpe at the Jefferies conference in London

Galapagos chief executive Onno van de Stolpe said he and Gilead’s Daniel O’Day toasted their $5.1bn “transformative” research deal with a glass of champagne in New York before they unveiled it to the biopharma world in July.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

More from Scrip

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of this interview with Scrip, Menarini’s Asia-Pacific CEO talks about the Italian group’s digital capabilities, including the impact made during a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The company is also revving up its business development and alliance engine, with around 14 candidates under evaluation at different stages at the regional level.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.